Statin Use Reduces Risk of Esophageal Adenocarcinoma in US Veterans with Barrett's Esophagus: A Nested Case-Control Study

Gastroenterology

Volumn 149, Issue 6, 2015, Pages 1392-1398

  Nguyen, Theresa ^a   Duan, Zhigang ^a   Naik, Aanand D ^a   Kramer, Jennifer R ^a   El Serag, Hashem B ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Chemoprevention; Drug; Esophageal Cancer; Pharmacoepidemiology; Statin

Indexed keywords

ATORVASTATIN; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; EZETIMIBE; FLUINDOSTATIN; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NICOTINIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PRAVASTATIN; PROTON PUMP INHIBITOR; ROSUVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; BARRETT ESOPHAGUS; CASE CONTROL STUDY; CHEMOPROPHYLAXIS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; ESOPHAGEAL ADENOCARCINOMA; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PRESCRIPTION; PRIORITY JOURNAL; RISK REDUCTION; SMOKING; TREATMENT DURATION; VETERAN; ADENOCARCINOMA; AGED; CANCER STAGING; COMPLICATION; DOSE RESPONSE; ESOPHAGEAL NEOPLASMS; INCIDENCE; MIDDLE AGED; PATHOLOGY; PHARMACOEPIDEMIOLOGY; PROCEDURES; RISK ASSESSMENT; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ADENOCARCINOMA; ADULT; AGED; BARRETT ESOPHAGUS; CASE-CONTROL STUDIES; CHEMOPREVENTION; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGEAL NEOPLASMS; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM STAGING; PHARMACOEPIDEMIOLOGY; RISK ASSESSMENT; SIMVASTATIN; UNITED STATES; VETERANS;

EID: 84945583711     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2015.07.009     Document Type: Article

References (23)

1. C. Hur, M.M. Miller, C.Y. Kong, and et al. Trends in esophageal adenocarcinoma incidence and mortality Cancer 119 2013 1149 1158
2. A.K. Rustgi, and H.B. El-Serag Esophageal carcinoma N Engl J Med 371 2014 2499 2509
3. G. Portale, J.A. Hagen, J.H. Peters, and et al. Modern 5-year survival of resectable esophageal adenocarcinoma: single institution experience with 263 patients J Am Coll Surg 202 2006 588 596
4. C. Duggan, L. Onstad, S. Hardikar, and et al. Association between markers of obesity and progression from Barrett's esophagus to esophageal adenocarcinoma Clin Gastroenterol Hepatol 11 2013 934 943
5. P. Yachimski, S. Wani, T. Givens, and et al. Preference of endoscopic ablation over medical prevention of esophageal adenocarcinoma by patients with Barrett's esophagus Clin Gastroenterol Hepatol 13 2015 84 90
6. F. Kastelein, M.C. Spaander, K. Biermann, et al. Probar-Study Group Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus Gastroenterology 141 2011 2000 2008
7. F. Kastelein, M.C. Spaander, E.W. Steyerberg, et al. ProBar Study Group Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett's esophagus Clin Gastroenterol Hepatol 11 2013 382 388
8. P.C. Konturek, G. Burnat, and E.G. Hahn Inhibition of Barrett's adenocarcinoma cell growth by simvastatin: involvement of COX-2 and apoptosis-related proteins J Physiol Pharmacol 58 suppl 3 2007 141 148
9. O.O. Ogunwobi, and I.L. Beales Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells Am J Gastroenterol 103 2008 825 837
10. M.R. Sadaria, A.E. Reppert, J.A. Yu, and et al. Statin therapy attenuates growth and malignant potential of human adenocarcinoma cells J Thorac Cardiovasc Surg 142 2011 1152 1160
11. S. Singh, A.G. Singh, P.P. Singh, and et al. Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett's esophagus: a systematic review and meta-analysis Clin Gastroenterol Hepatol 11 2013 620 629
12. I.L.P. Beales, A. Hensley, and Y. Loke Reduced esophageal cancer incidence in statin users, particularly with cyclo-oxygenase inhibition World J Gastrointest Pharmacol Ther 4 2013 69 79
13. D.M. Nguyen, P. Richardson, and H.B. El-Serag Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus Gastroenterology 138 2010 2260 2266
14. F. Kastelein, M. Spaaner, K. Biermann, and et al. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus Gastroenterology 141 2011 2000 2008
15. D.M. Nguyen, H.B. El-Serag, L. Henderson, and et al. Medication usage and the risk of neoplasia in patients with Barrett's esophagus Clin Gastroenterol Hepatol 7 2009 1299 1304
16. E.D. Kantor, L. Onstad, P.L. Blount, and et al. Use of statin medications and risk of esophageal adenocarcinoma in persons with Barrett's esophagus Cancer Epidemiol Biomarkers Prev 21 2012 456 461
17. H.B. El-Serag, M. Wieman, and P. Richardson The use of acid-decreasing medication in veteran patients with gastro-oesophageal reflux disorder with and without Barrett's oesophagus Aliment Pharmacol Ther 27 2008 1293 1299
18. T. Nguyen, N. Khalaf, D. Ramsey, and et al. Statin use is associated with a decreased risk of Barrett's esophagus Gastroenterology 147 2014 314 323
19. R.A. Deyo, D.C. Cherkin, and M.A. Ciol Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases J Clin Epidemiol 45 1992 613 619
20. J.H. Lubin, and M.H. Gail Biased selection of controls for case-control analyses of cohort studies Biometrics 40 1984 63 75
21. S.E. Choi, K.E. Perzan, A.C. Tramontano, and et al. Statins and aspirin for chemoprevention in Barrett's esophagus: results of a cost-effectiveness analysis Cancer Prev Res 7 2014 341 350
22. R.O. Morgan, L.A. Petersen, J.C. Hasche, and et al. VHA pharmacy use in veterans with Medicare drug coverage Am J Manag Care 15 2009 e1 e8
23. A. Chak, N.S. Buttar, N.R. Foster, and et al. Metformin does not reduce markers of cell proliferation in esophageal tissues of patients with Barrett's esophagus Clin Gastroenterol Hepatol 13 2015 665 672